|Mr. Haruo Naito||CEO, Representative Corp. Officer & Director||1.02M||N/A||1947|
|Mr. Gary Hendler||Sr. VP & Pres of EMEA Region||1.22M||N/A||1966|
|Dr. Lynn D. Kramer FAAN, M.D.||VP & Group Chief Clinical Officer - Neurology Bus. Group||1.04M||N/A||1950|
|Ms. Yanhui Feng||Sr. VP||962.17k||N/A||1972|
|Dr. Nadeem Sarwar Ph.D.||Pres||N/A||N/A||N/A|
|Mr. Ryohei Yanagi||Exec. VP & CFO||N/A||N/A||1962|
|Ms. Sayoko Sasaki||Chief IR Officer & VP||N/A||N/A||1968|
|Mr. Kenta Takahashi||Exec. VP, Gen. Counsel & Intellectual Property Mang.||N/A||N/A||1959|
|Mr. Mitsuaki Tanaka||Chief Compliance Officer, Internal Control, Chief Information Security Officer & VP||N/A||N/A||1962|
|Mr. Yasushi Okada||Representative Corp. Officer, COO, Industry Affairs, China Bus. & Data Integrity||N/A||N/A||1958|
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. Eisai Co., Ltd. has a research collaboration agreement with Wren Therapeutics Ltd. for the discovery of small molecules that target synuclein for the potential treatment of synucleinopathies, including Parkinson's disease and dementia with Lewy bodies; and a collaboration with BioLabs for the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups to innovate in the field of neurological diseases. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.
Eisai Co., Ltd.’s ISS governance QualityScore as of 26 September 2021 is 4. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 10; Compensation: 4.